Porous Nanocomposite for Cancer Cell Studies
Official patent title
Inhibition of cancer cell viability
Arabic title: تثبيط حيوية الخلايا السرطانية
Invention
Invention
Problem
Conventional chemotherapy can have low selectivity, poor bioavailability, resistance, and dose-limiting toxicity. Nanomaterials may offer different cellular interactions, but they introduce concerns about consistency, clearance, long-term toxicity, scale-up, and regulation.
Why it matters
A structurally characterized inorganic nanocomposite with reproducible cell-response data could provide an early platform for studying material composition, porosity, morphology, and anticancer activity in vitro.
Approach
The method exposes cancer cells to a porous g-C3N4/MoO3/MgAl2O4 nanocomposite at defined mass ratios and concentrations. Metal-oxide particles are dispersed on curled and wrinkled graphitic carbon-nitride nanosheets and platelets.
Who may benefit
Potential beneficiaries include cancer-nanotechnology laboratories, inorganic-material researchers, preclinical oncology groups, pharmaceutical discovery teams, and organizations developing cell-based nanomaterial assays.
Potential value
The disclosure connects a defined three-component nanocomposite, measured crystal and pore structure, and two-dimensional morphology with at least 85% growth inhibition in specified HepG-2 and MCF-7 in-vitro cancer-cell tests.
Background
Background
Chemotherapy can be limited by off-target toxicity, low therapeutic index, solubility, bioavailability, and drug resistance. Nanomaterials are investigated as carriers or active materials because size, shape, surface area, and functionalization can alter cell interactions. However, nanomedicine also faces unresolved questions about biocompatibility, clearance, accumulation, manufacturing consistency, cost, and regulatory approval. The patent evaluates a graphitic carbon-nitride and mixed-metal-oxide composite directly against liver and breast cancer-cell models, providing material characterization alongside cell-viability measurements.
Technology overview
Technology overview
The nanocomposite contains g-C3N4, MoO3, and MgAl2O4 at a broad 5–15:2–7:75–95 mass relationship, with a narrower disclosed range of 9–11:4–6:84–86. It has 8–12 m²/g BET area, 5–15 nm average pore diameter, and metal-oxide nanoparticles on porous carbon-nitride sheets. Claims expose cells to 25–500 μg/mL and report at least 85% growth inhibition. HepG-2 and MCF-7 tests use narrower concentration ranges, with reported IC50 values of approximately 62.35 and 108.19 μg/mL, respectively.
Potential applications
Potential applications
- Preclinical in-vitro evaluation of anticancer nanomaterials.
- Liver-cancer and breast-cancer cell-viability studies.
- Structure–activity research on porous mixed-oxide nanocomposites.
- Cell-based screening of drug-free inorganic material formulations.
Evidence-supported advantages
Evidence-supported advantages
- Combines graphitic carbon nitride, MoO3, and MgAl2O4 in defined mass ranges.
- Provides XRD, TEM, SAED, surface-area, and pore measurements.
- Uses a porous two-dimensional support with dispersed metal-oxide particles.
- Reports at least 85% growth inhibition in the claimed in-vitro method.
- Does not require added cobalt, folic acid, rubicin drug, or photosensitizer in specified embodiments.
Development stage
Development stage
Nanocomposite synthesis, structural and porosity characterization, and in-vitro HepG-2 and MCF-7 viability tests are described; normal-cell selectivity, animal safety and efficacy, and clinical performance were not established. The development stage was not independently verified.
Commercial opportunity
Commercial opportunity
The material may support early nanomedicine research partnerships or licensing. Translation requires normal-cell selectivity, mechanism, uptake and clearance studies, hemocompatibility, biodistribution, chronic toxicity, formulation and sterilization work, animal efficacy, reproducible scale-up, regulatory characterization, and clinical trials before therapeutic use could be considered.
Patent classifications
Patent classifications
WIPO IPC
- A61K33/06Preparations for medical, dental or toiletry purposes
- A61K9/16Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
CPC
- A61K9/16Preparations for medical, dental or toiletry purposes
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
- A61K9/5107Preparations for medical, dental or toiletry purposes
- A61K33/06Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
Inventors
Inventors
- First inventorMohamed Khairy Abdel Fattah Omran
- InventorBabiker Yagoub Elhadi Abdulkhair
Keywords
Keywords
- g-C3N4
- MoO3
- MgAl2O4
- nanocomposite
- cancer cell viability
- HepG-2
- MCF-7
- in-vitro oncology
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.